Navigating Medication Options for Smoking Cessation in Mental Health Settings

Lesson Materials

LEARNING OBJECTIVES

  1. Describe the tobacco use prevalence among persons with behavioral health conditions
  2. Introduce the clinical practice guidelines evidence-based recommendation on pharmacologic treatment options for patients with tobacco dependence
  3. Compare various tobacco treatment medications, including the safety and efficacy data, for the management of tobacco cessation
  4. Examine tobacco treatment medications, including doses, routes, and frequency of administration

Speaker: Karen Hudmon, DrPH, MS, RPh, CTTS, Professor of Pharmacy Practice, Purdue University College of Pharmacy

Click here to download the presentation slides

CME/CEU:  Eligible professionals can earn one-hour of free continuing education for watching the video and completing the associated quiz.

Active date: 6/01/2021    Expiration: 6/01/2022

ACCREDITATION STATEMENT
In support of improving patient care, Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical

Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

  • Indiana University School of Medicine designates this activity for a maximum of 1.0 ANCC contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

  • Indiana University School of Medicine designates this activity for 1.0 ACPE contact hours. Pharmacists should only claim credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Physicians

  • Indiana University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Social Workers & Other Behavioral Health Providers

  • This activity qualifies for 1.0 Category I Continuing Education Units for Social Workers, Clinical Social Workers, Marriage and Family Therapists, Marriage and Family Therapy Associates, Mental Health Counselors, Mental Health Counselor Associates, Addiction Counselors, and Clinical Addiction Counselors as outlined by the Indiana Behavioral Health and Human Services Licensing Board.

Disclosure Summary
Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that IUSM may identify and resolve any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor.

There are no relevant financial relationships with a commercial interest for anyone who was in control of the content of this activity.

*Indiana University School of Medicine (IUSM) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

IMPORTANT: Once you have finished watching the video, a quiz box will appear below the video box which will allow you to complete the associated quiz.

Reference list:

  • Fiore MC, Jaén CR, Baker TB, et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service.
  • National Mental Health Services Survey (N-MHSS): 2017. Data on Mental Health Treatment Facilities; National Survey of Substance Abuse Treatment Services (N-SSATS): 2017. Data on Substance Abuse Treatment Facilities.
  • Hajek P, McRobbie H, Gillison F. (2007). Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. Prev Med 44:230–234.
  • Cahill K, Stevens S, Perera R, Lancaster T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 31;(5):CD009329.
  • Choi JH, Dresler CM, Norton MR, Strahs KR. (2003). Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5:635–644.
  • Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 11:CD000146.
  • Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, et al. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387(10037):2507–2250.
  • Barzilai DA, Goodwin MA, Zyzanski SJ, Stange KC. (2001). Does health habit counseling affect patient satisfaction? Prev Med 33:595–599.
  • Hughes JR. (2007). Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9:315–27.
  • Pomp ER, Rosendaal FR, Doggen CJM. (2007). Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hemotol 83:97-102.
  • World Health Organization. (2010). Medical Eligibility Criteria for Contraceptive Use, 4th ed. Geneva, Switzerland: World Health Organization, pp. 1–121. Retrieved January 9, 2019, from www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/. </span>